Dafna Capital Management LLC Decreased Its Stake in Loxo Oncology INC (LOXO) by $3.96 Million

Loxo Oncology, Inc. (NASDAQ:LOXO) LogoInvestors sentiment increased to 1.74 in 2018 Q2. Its up 0.58, from 1.16 in 2018Q1. It improved, as 8 investors sold LOXO shares while 57 reduced holdings. 58 funds opened positions while 55 raised stakes. 28.62 million shares or 4.87% less from 30.09 million shares in 2018Q1 were reported. Jpmorgan Chase And has 56,542 shares for 0% of their portfolio. Blackrock Incorporated owns 2.10 million shares or 0.02% of their US portfolio. Frontier Capital Mgmt Limited Liability has invested 0.03% of its portfolio in Loxo Oncology, Inc. (NASDAQ:LOXO). Schwab Charles Mgmt stated it has 129,016 shares or 0.02% of all its holdings. State Bank Of America De reported 0% in Loxo Oncology, Inc. (NASDAQ:LOXO). American Int Group Inc has invested 0.01% in Loxo Oncology, Inc. (NASDAQ:LOXO). Ameriprise has 219,121 shares. Metropolitan Life Insur Ny stated it has 8,554 shares. Axa holds 0.04% or 66,600 shares. Marshall Wace Llp reported 1,847 shares. Cambridge Research Advisors holds 2,460 shares or 0% of its portfolio. Rhumbline Advisers reported 25,651 shares. Art Advsr Ltd holds 0.14% or 19,496 shares. 527 are owned by Acadian Asset Mngmt Llc. X Management Limited Co reported 300 shares.

Since June 7, 2018, it had 0 insider buys, and 22 selling transactions for $303.57 million activity. 1,500 shares valued at $280,870 were sold by Burstein Jennifer on Monday, July 9. 20,000 shares were sold by Bilenker Joshua H., worth $3.32 million on Wednesday, September 12. $1.59 million worth of Loxo Oncology, Inc. (NASDAQ:LOXO) was sold by Van Naarden Jacob. Fuhrman Alan sold $467,437 worth of stock or 2,625 shares. Kunkel Lori Anne also sold $7.06M worth of Loxo Oncology, Inc. (NASDAQ:LOXO) shares. The insider Flaherty Keith T. sold $8.68M.

Dafna Capital Management Llc decreased its stake in Loxo Oncology Inc (LOXO) by 12.59% based on its latest 2018Q2 regulatory filing with the SEC. Dafna Capital Management Llc sold 22,862 shares as the company’s stock declined 8.98% while stock markets rallied. The hedge fund held 158,675 shares of the health care company at the end of 2018Q2, valued at $27.53M, down from 181,537 at the end of the previous reported quarter. Dafna Capital Management Llc who had been investing in Loxo Oncology Inc for a number of months, seems to be less bullish one the $4.30B market cap company. The stock increased 0.57% or $0.79 during the last trading session, reaching $140.42. About 353,781 shares traded or 9.87% up from the average. Loxo Oncology, Inc. (NASDAQ:LOXO) has risen 119.31% since December 2, 2017 and is uptrending. It has outperformed by 103.69% the S&P500.

More notable recent Loxo Oncology, Inc. (NASDAQ:LOXO) news were published by: Streetinsider.com which released: “Loxo Oncology (LOXO) PT Lowered to $215 at JMP Securities – StreetInsider.com” on November 13, 2018, also Seekingalpha.com with their article: “FDA OKs Loxo’s Vitrakvi – Seeking Alpha” published on November 26, 2018, Seekingalpha.com published: “Loxo Oncology: Out Of The Frying Pan And Into The Fire (Part 2/2) – Seeking Alpha” on August 17, 2018. More interesting news about Loxo Oncology, Inc. (NASDAQ:LOXO) were released by: Seekingalpha.com and their article: “LOXO’s ESMO Update On Larotrectinib – Changing Treatment Paradigms – Seeking Alpha” published on October 25, 2018 as well as Seekingalpha.com‘s news article titled: “LOXO-292 shows positive effect in RET-altered thyroid cancer in Phase 1/2 study – Seeking Alpha” with publication date: October 08, 2018.

Loxo Oncology, Inc. (NASDAQ:LOXO) Ratings Coverage

Among 8 analysts covering Loxo Oncology (NASDAQ:LOXO), 6 have Buy rating, 0 Sell and 2 Hold. Therefore 75% are positive. Loxo Oncology has $235 highest and $165 lowest target. $210.14’s average target is 49.65% above currents $140.42 stock price. Loxo Oncology had 13 analyst reports since June 4, 2018 according to SRatingsIntel. The firm has “Market Perform” rating by IFS Securities given on Tuesday, June 5. The stock of Loxo Oncology, Inc. (NASDAQ:LOXO) earned “Buy” rating by JMP Securities on Tuesday, November 27. The stock of Loxo Oncology, Inc. (NASDAQ:LOXO) earned “Buy” rating by Citigroup on Wednesday, October 24. Morgan Stanley maintained Loxo Oncology, Inc. (NASDAQ:LOXO) on Thursday, October 11 with “Overweight” rating. Stifel Nicolaus maintained the stock with “Buy” rating in Monday, June 4 report. The company was maintained on Monday, June 4 by JMP Securities. The stock has “Overweight” rating by Morgan Stanley on Monday, June 4. JMP Securities maintained the shares of LOXO in report on Tuesday, November 13 with “Market Outperform” rating. Citigroup maintained Loxo Oncology, Inc. (NASDAQ:LOXO) rating on Friday, November 16. Citigroup has “Buy” rating and $213 target.

Loxo Oncology, Inc. (NASDAQ:LOXO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.